1-1-2016

An Individual With Human Immunodeficiency Virus, Dementia, and Central Nervous System Amyloid Deposition

Raymond Scott Turner
Melanie Chadwick
Wesley A Horton
Gary L. Simon
George Washington University
Xiong Jiang

See next page for additional authors

Follow this and additional works at: http://hsr.himmelfarb.gwu.edu/smhs_medicine_facpubs
Part of the Nervous System Diseases Commons, and the Virus Diseases Commons

APA Citation
Diagnostic Assessment & Prognosis

An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition

Raymond Scott Turner\textsuperscript{a},*, Melanie Chadwick\textsuperscript{a}, Wesley A. Horton\textsuperscript{a}, Gary L. Simon\textsuperscript{b}, Xiong Jiang\textsuperscript{c}, Giuseppe Esposito\textsuperscript{d}

\textsuperscript{a}Department of Neurology, Georgetown University, Washington, DC, USA
\textsuperscript{b}Department of Infectious Diseases, George Washington University, Washington, DC, USA
\textsuperscript{c}Department of Neuroscience, Georgetown University, Washington, DC, USA
\textsuperscript{d}Department of Radiology, Georgetown University, Washington, DC, USA

Abstract

Human immunodeficiency virus (HIV)–associated neurocognitive disorder (HAND) is found in 30%–50% of individuals with HIV infection. To date, no HIV+ individual has been reported to have a positive amyloid PET scan. We report a 71-year-old HIV+ individual with HAND. Clinical and neuropsychologic evaluations confirmed a progressive mild dementia. A routine brain MRI was normal for age. [18F]Fluorodeoxyglucose–PET revealed mild hypermetabolism in bilateral basal ganglia and hypometabolism of bilateral parietal cortex including the posterior cingulate/precuneus. Resting state functional MRI revealed altered connectivity as found with individuals with mild AD. CSF examination revealed a low A\textsubscript{\beta}42/tau index but a low phospho-tau. An amyloid PET/CT with [18F]florbetaben revealed pronounced cortical radiotracer deposition. This case report suggests that progressive dementia in older HIV+ individuals may be due to HAND, AD, or both. HIV infection does not preclude CNS A\textsubscript{\beta}/amyloid deposition. Amyloid PET imaging may be of value in distinguishing HAND from AD pathologies.

© 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: 
Human immunodeficiency virus; HIV; HIV-associated neurocognitive disorder; HAND; Dementia; Alzheimer’s disease; Amyloid PET; Functional MRI; Biomarker

1. Introduction

More than 36.9 million individuals worldwide are infected with human immunodeficiency virus (HIV) in 2014 [1]. HIV infection has largely changed from a fatal illness to a chronic manageable condition since the introduction of combination antiretroviral treatment (cART) in 1996. HIV-infected adults older than 55 years comprise the fastest growing age group in the HIV+ population [2]. HIV-associated neurocognitive disorder (HAND) occurs in 30%–50% of HIV+ individuals treated with cART [3].

The etiology of HAND remains unclear but may be due to viral infection and inflammation accelerating CNS aging [4] and decreasing cognitive reserve. It is currently unknown whether chronic HIV infection and/or treatment are risk factors for Alzheimer’s disease (AD). As an increasing fraction of the HIV+ populace advances into the geriatric age range, clinicians will be challenged to differentiate HAND from other dementias of aging, including AD.

Putative biomarkers of AD pathology, including cerebrospinal fluid (CSF) proteomics—A\textsubscript{\beta}/amyloid, tau, phospho-tau, and others, and amyloid PET neuroimaging are supportive of a clinical diagnosis of AD pathology [5] in HIV-uninfected individuals. Only one case of HAND and biomarker-supported AD has been reported—with abnormal [18F]fluorodeoxyglucose-PET and CSF...
proteomics [6]. However, a review of CSF AD biomarkers in subjects with HAND reveals low amyloid levels in both diagnoses, increased phospho-tau in AD, and inconsistent tau levels in HAND [7]. To date, no HIV+ individual has been reported to have a positive amyloid PET scan. In fact, Ances et al. [8] suggest that HAND is not associated with increased CNS fibrillar amyloid as detected by amyloid PET imaging because all five subjects examined were negative, but the oldest was 67 years old. Given the aging HIV+ populace, we report the sentinel case of a possible new emerging epidemic of HAND/AD.

2. Methods and results

2.1. Case study

The subject is a 71 year-old man with a 14-year history of HIV infection diagnosed after presenting with flu-like symptoms and a viral pneumonia. He was subsequently treated with cART. He and his wife noted mild short-term memory problems for 5 years with insidious onset and a more noticeable decline in the last 3 years. His symptoms manifested by comprehension difficulty, forgetting recent conversations, and difficulty with multitasking. Functionally, he stated that he took longer to complete projects and sometimes made mistakes. He could no longer work as an attorney. His spouse stated that he had trouble learning new skills such as using his cellular telephone. As calculations became more challenging, his spouse assumed household financial management. He currently shops independently but requires a list. He performs personal care and basic activities of daily living with minimal or no assistance. He describes his mood as fearful of his cognitive disorder. He remains socially active, exercises daily, and enjoys weekly religious services. He denies aggression, anxiety, agitation, hallucinations, delusions, paranoia, and suicidal ideation. He has a long-standing history of sleep problems. His spouse also reports frequent (2–3 times a week) episodes of violent movements and screaming while dreaming. The patient reports these events as acting out his dreams. His spouse also reports occasional jerks of his extremities during sleep. Review of clinical records indicates a stable HIV infection with consistent compliance with cART (most recently abacavir, lamivudine, darunavir, and ritonavir). He also takes atorvastatin for hypercholesterolemia. There is no history of CNS infection or injury, stroke, transient ischemic attack, or alcohol or drug abuse. He had one episode of loss of consciousness with a minor head injury secondary to syncope in 2002. His mother died at age 89 years with probable AD; his father died at age 71 years with parkinsonism and dementia.

His physical and neurologic examination was remarkable only for cognitive impairment. His Mini-Mental State Examination [9] score was 22/30, and Montreal Cognitive Assessment [10] score was 20/30. He recalled zero of five words on delayed recall. He had difficulty with repetition and gave concrete answers to similarities. He named only

<table>
<thead>
<tr>
<th>Task</th>
<th>Evaluation 1</th>
<th>Evaluation 2 (27 mo later)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Working memory and information processing speed</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Working Memory Index</td>
<td>Average (50th percentile)</td>
<td>Low average (23rd percentile)</td>
</tr>
<tr>
<td>Arithmetic</td>
<td>High average (75th percentile)</td>
<td>Average (50th percentile)</td>
</tr>
<tr>
<td>Digit span</td>
<td>Average (5F/4B; 25th percentile)</td>
<td>Borderline (5F/2B; 9th percentile)</td>
</tr>
<tr>
<td>Processing speed index</td>
<td>Borderline (8th percentile)</td>
<td>Impaired (5th percentile)</td>
</tr>
<tr>
<td>Digit symbol coding</td>
<td>Impaired (5th percentile)</td>
<td>Impaired (5th percentile)</td>
</tr>
<tr>
<td>Symbol search</td>
<td>Low average (16th percentile)</td>
<td>Borderline (9th percentile)</td>
</tr>
<tr>
<td>Executive functioning</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rey complex figure copy</td>
<td>Impaired: poor planning and organization; inaccurate</td>
<td>Impaired: poor planning and organization; inaccurate</td>
</tr>
<tr>
<td>WAIS-IV picture completion</td>
<td>Borderline (9th percentile)</td>
<td>Average (50th percentile)</td>
</tr>
<tr>
<td>WAIS-III picture arrangement</td>
<td>Borderline (9th percentile)</td>
<td>Low average (16th percentile)</td>
</tr>
<tr>
<td>Language</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phonemic verbal fluency (FAS)</td>
<td>Superior (Σ = 60, 91st percentile)</td>
<td>Low average (Σ = 29, 13th percentile)</td>
</tr>
<tr>
<td>Semantic verbal fluency (animals)</td>
<td>Low average (Σ = 18, 23rd percentile)</td>
<td>Impaired (Σ = 11, 1st percentile)</td>
</tr>
<tr>
<td>Boston naming test</td>
<td>Impaired (47/60 correct)</td>
<td>Impaired (40/60 correct)</td>
</tr>
<tr>
<td>Repeatable battery for the assessment of neurocognitive status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total score</td>
<td>Not tested</td>
<td>Impaired (1st percentile)</td>
</tr>
<tr>
<td>Attention</td>
<td>Not tested</td>
<td>Impaired (1st percentile)</td>
</tr>
<tr>
<td>Immediate memory</td>
<td>Not tested</td>
<td>Impaired (&lt;1st percentile)</td>
</tr>
<tr>
<td>Visuospatial/constructional</td>
<td>Not tested</td>
<td>Low average (14th percentile)</td>
</tr>
<tr>
<td>Language</td>
<td>Not tested</td>
<td>Impaired (&lt;1st percentile)</td>
</tr>
<tr>
<td>Delayed memory</td>
<td>Not tested</td>
<td>Low average (14th percentile)</td>
</tr>
<tr>
<td>Fine motor speed and coordination</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grooved pegboard dominant (R)</td>
<td>Impaired (Σ = 121 s, 2nd percentile)</td>
<td>Impaired (Σ = 121 s, 2nd percentile)</td>
</tr>
<tr>
<td>Grooved pegboard nondominant</td>
<td>Impaired (Σ = 133 s, 3rd percentile)</td>
<td>Impaired (Σ = 121 s, 2nd percentile)</td>
</tr>
</tbody>
</table>

WAIS, Wechsler Adult Intelligence Scale.

B Functional MRI reveals impaired connectivity.  C Quantitative analysis of functional MRI.

D [18F]Florbetaben PET demonstrates marked cortical amyloid deposition.
seven words beginning with F in 1 minute. His paragraph recall was 5/25 immediately and 2/25 after 30 minutes. He underwent two neuropsychological evaluations 27 months apart—both consistent with dementia—which revealed interval decline of working memory and verbal fluency (Table 1). His laboratory workup revealed a chronic subnormal CD4 T cell count (~300–350/μL), depressed CD4/CD8 ratio (0.75), and nondetectable plasma HIV RNA (<20 copies/μL); all other blood tests were normal. A polysomnogram revealed no significant sleep disordered breathing with minimal periodic limb movements unassociated with arousals and sleep fragmentation.

A routine brain MRI revealed atrophy and white matter changes consistent with age. [18F]fluorodeoxyglucose-PET revealed mild hypermetabolism in bilateral basal ganglia (consistent with HAND [11]) and marked hypometabolism of parietal cortex including the posterior cingulate/precuneus (consistent with AD; Fig. 1A). The SUVr is the ratio of the individual standardized uptake value (SUV) for each of the brain regions compared with the SUV of the cerebellar cortex. Specifically, the SUVr values were as follows: posterior cingulate 1.99, parietal 1.95, temporal 1.89, frontal 1.81, anterior cingulate 1.6, occipital 1.53, average 1.8. FDG, [18F]fluorodeoxyglucose; SD, standard deviation; AD, Alzheimer’s disease; SEM, standard error of the mean.

This case report suggests that progressive dementia in older HIV+ individuals may be due to HAND, AD, or both. We propose that the individual described here may have a mixed dementia—HAND and probable AD, but dementia due to either diagnosis alone cannot be excluded. This case suggests that CNS HIV infection does not preclude Aβ/amyloid deposition. In fact, chronic HIV infection may be a risk factor for AD because of neuroinflammation, accelerated CNS aging, and reduced cognitive reserve—thus constituting a “double-hit.” In support of this notion, Cysique et al. [13] report that CSF biomarker profiles of HIV+ individuals suggest a 10× higher risk for AD compared with age-matched uninfected subjects. Although CNS HIV infection may be the primary etiology of HAND, a role for cART is also possible because of adverse effects of chronic treatment. Consistent with this notion, Caniglia et al. [14] report that cART regimens with a high CNS penetration effectiveness score increase the risk of HIV dementia. Antiretroviral medications disrupt microglial phagocytosis of β-amyloid and increase its production by neurons in vitro [15]. In contrast, Lan et al. [16] suggest that cART inhibits Aβ clearance in macrophages and Aβ production in neurons, but these effects do not significantly alter CNS Aβ accumulation in a mouse model. Clearly, the potential interactions of HAND and AD pathologies leading to dementia, including a possible role of cART, require further research.

Cognitive decline in HAND may be mediated in part by CNS Aβ/amyloid accumulation [17]. Although pathologic studies of brain show that HIV increases intracellular and possibly extracellular Aβ42, Ortega and Ances [18] suggest that HIV+ individuals are not at increased risk for AD. Amyloid PET neuroimaging will be useful to distinguish putative neuropathologies of HAND—either HIV associated, amyloid associated, or both. However, to date, only five individuals with HAND have undergone amyloid PET imaging—all were negative, but the oldest subject was 67 years old [8]. Longitudinal studies of older HIV-infected versus uninfected cohorts are now needed to further define the potential interactions of HIV with AD—clinically, pathologically, and effects on prognostic, diagnostic, and theragnostic biomarkers, including fMRI.

Older individuals with HAND may be included in the target population of a new study designed to determine the clinical utility of amyloid imaging in subjects with dementia of uncertain etiology (IDEAS, or Imaging Dementia-Evidence for Amyloid Scanning, clinicaltrials.gov #NC T02420756). Furthermore, the optimal cART regimen for HAND remains unclear; some investigators propose a regimen with a high CNS penetration effectiveness to improve efficacy. The safety and efficacy of Food and Drug Administration-approved medications for dementia due to AD in subjects with coexisting HAND is unclear because HIV infection is invariably exclusionary in MCI and AD trials. Antiamyloid and other therapies for MCI and AD now under development may also be effective for older HIV+ individuals. This sentinel case raises new questions regarding diagnosis, pathogenesis, and treatment of dementia in older HIV+ subjects that require further studies.
RESEARCH IN CONTEXT

1. Systematic review: Since the introduction of combination antiretroviral therapy, human immunodeficiency virus (HIV) has become a manageable chronic disorder. As a result, an increasing fraction of the HIV+ populace is reaching the geriatric age range and thus at risk for Alzheimer’s disease (AD). About 30%–50% of HIV+ individuals will develop HIV-associated neurocognitive disorders (HANDs). Amyloid PET imaging has not yet been systematically examined in older individuals with HAND.

2. Interpretation: We report the first HIV+ individual with a positive amyloid positron emission tomography (PET) scan. This case report suggests that chronic HIV infection does not preclude central nervous system (CNS) amyloid deposition. Individuals with HIV may develop cognitive decline because of HAND, AD, or both.

3. Future directions: Amyloid PET imaging may be useful to distinguish HIV-associated pathology and/or CNS amyloid deposition in demented individuals. Functional magnetic resonance imaging (fMRI) may also be a useful biomarker. Anti-amyloid treatments now under development for mild cognitive impairment, and AD may be effective for some individuals with HAND.

References


